Abstract
Background Recurrent glioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor that is resistant to existing treatments. Recently, we reported that activated autologous natural killer (NK) cell therapeutics induced a marked increase in survival of some patients with recurrent GBM.
Methods To identify biomarkers that predict responsiveness to NK therapeutics, we examined immune profiles in tumor tissues using NanoString nCounter analysis and compared the profiles between 5 responders and 7 non-responders. Through a three-step data analysis, we identified three candidate biomarkers (TNFRSF18, TNFSF4, and IL12RB2) and performed validation with qRT-PCR. We also performed immunohistochemistry and an NK cell migration assay to assess the function of these genes.
Results Responders had higher expression of many immune-signaling genes compared with non-responders, which suggests an immune-active tumor microenvironment in responders. The random forest model that identified TNFRSF18, TNFSF4, and IL12RB2 showed a 100% accuracy (95% CI: 73.5%–100%) for predicting the response to NK therapeutics. The expression levels of these three genes by qRT-PCR were highly correlated with the NanoString levels, with high Pearson’s correlation coefficients (0.419 (TNFRSF18), 0.700 (TNFSF4), and 0.502 (IL12RB2)); their prediction performance also showed 100% accuracy (95% CI: 73.54%–100%) by logistic regression modeling. We also demonstrated that these genes were related to cytotoxic T cell infiltration and NK cell migration in the tumor microenvironment.
Conclusions We identified TNFRSF18, TNFSF4, and IL12RB2 as biomarkers that predict response to NK cell therapeutics in recurrent GBM, which might provide a new treatment strategy for this highly aggressive tumor.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by a grant (HI16C1559) from the Korea Health Technology R&D Project through The Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, and supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. NRF-2019R1A6A1A03032888).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Bundang CHA Medical Center (#2012-12-172, #2021-01-024). Informed consent was obtained from each patient before the clinical trial.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All expression data are available in the GEO Database (https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE207753.
List of abbreviations
- AKC
- Autologous activated NK cells
- ATCC
- American Type Culture Collection
- AUC
- Area under the ROC curve
- CFSE
- Carboxyfluorescein succinimidyl ester
- CI
- Confidence interval
- DEG
- Differentially expressed genes
- FFPE
- Formalin-fixed paraffin-embedded
- GBM
- Glioblastoma multiforme
- KHIDI
- Korea Health Industry Development Institute
- NK
- Natural killer
- OS
- Overall survival
- PBMC
- Peripheral blood mononuclear cells
- PCA
- Principal component analysis
- PFS
- Progression-free survival
- TAM
- Tumor-associated macrophages
- TMB
- Tumor mutation burden
- Treg
- Regulatory T